DrugPatentWatch Database Preview
Janssen Prods Company Profile
What is the competitive landscape for JANSSEN PRODS, and when can generic versions of JANSSEN PRODS drugs launch?
JANSSEN PRODS has seven approved drugs.
There are thirty-two US patents protecting JANSSEN PRODS drugs.
There are eight hundred and thirty-one patent family members on JANSSEN PRODS drugs in sixty-six countries and one hundred and forty-three supplementary protection certificates in thirteen countries.
Summary for Janssen Prods
| International Patents: | 831 |
| US Patents: | 32 |
| Tradenames: | 6 |
| Ingredients: | 6 |
| NDAs: | 7 |
Drugs and US Patents for Janssen Prods
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Prods | PREZISTA | darunavir ethanolate | TABLET;ORAL | 021976-002 | Feb 25, 2008 | AB | RX | Yes | No | 8,597,876*PED | ➤ Sign Up | Y | ➤ Sign Up | ||
| Janssen Prods | PREZISTA | darunavir ethanolate | TABLET;ORAL | 021976-005 | Dec 18, 2008 | RX | Yes | No | 9,889,115 | ➤ Sign Up | ➤ Sign Up | ||||
| Janssen Prods | EDURANT | rilpivirine hydrochloride | TABLET;ORAL | 202022-001 | May 20, 2011 | RX | Yes | Yes | 6,838,464 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Janssen Prods | SYMTUZA | cobicistat; darunavir ethanolate; emtricitabine; tenofovir alafenamide fumarate | TABLET;ORAL | 210455-001 | Jul 17, 2018 | RX | Yes | Yes | 8,754,065 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Janssen Prods | YONDELIS | trabectedin | POWDER;IV (INFUSION) | 207953-001 | Oct 23, 2015 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | |||||
| Janssen Prods | PREZISTA | darunavir ethanolate | TABLET;ORAL | 021976-002 | Feb 25, 2008 | AB | RX | Yes | No | 7,700,645*PED | ➤ Sign Up | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Janssen Prods
Paragraph IV (Patent) Challenges for JANSSEN PRODS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
Non-Orange Book US Patents for Janssen Prods
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 5,914,331 | Antiviral activity and resolution of 2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane | ➤ Sign Up |
| 6,153,751 | Method and compositions for the synthesis of BCH-189 and related compounds | ➤ Sign Up |
| 5,827,727 | Method of resolution of 1,3-oxathiolane nucleoside enantiomers | ➤ Sign Up |
| 8,088,770 | Modulators of pharmacokinetic properties of therapeutics | ➤ Sign Up |
| 5,852,027 | Antiviral 1,3-dioxolane nucleoside analogues | ➤ Sign Up |
| 5,204,466 | Method and compositions for the synthesis of BCH-189 and related compounds | ➤ Sign Up |
| 6,812,233 | Therapeutic nucleosides | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Janssen Prods Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2487163 | ➤ Sign Up |
| Spain | 2336009 | ➤ Sign Up |
| Japan | 5507791 | ➤ Sign Up |
| Iceland | 6689 | ➤ Sign Up |
| Australia | 2003271740 | ➤ Sign Up |
| Russian Federation | 2382647 | ➤ Sign Up |
| Austria | 494288 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Janssen Prods Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0036 | France | ➤ Sign Up | PRODUCT NAME: COMBINAISON DE RILPIVIRINE ET TOUTES SES FORMES THERAPEUTIQUEMENT EQUIVALENTES PROTEGEES PAR LE BREVET DE BASE, TELLES QUE LES SELS D'ADDITION PHARMACEUTIQUEMENT ACCEPTABLES DE RILPIVIRINE, Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE ET DE TENOFOVIR, EN PARTICULIER LE TENOFOVIR DISOPROXIL FUMARATE; REGISTRATION NO/DATE: EU/1/11/737/001 20111128 |
| 0859 | Netherlands | ➤ Sign Up | PRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN ATAZANAVIR, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER ATAZANAVIRSULFAAT; REGISTRATION NO/DATE: EU/1/15/1025 20150715 |
| 2015000092 | Germany | ➤ Sign Up | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH UNBEDENKLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/830/001-002 20130524 |
| 0860 | Netherlands | ➤ Sign Up | PRODUCT NAME: COBICISTAT, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN TENOFOVIR-ALAFENAMIDE, DAN WEL EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIR-ALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/15/1061 20151123 |
| 2015037 | Lithuania | ➤ Sign Up | PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM + EMTRICITABINUM; REGISTRATION NO/DATE: EU/1/11/737/001 2011 11 28, EU/1/11/737/002 20111128 |
| 073 | Luxembourg | ➤ Sign Up | 91073, EXPIRES: 20160131 |
| 0120012 00058 | Estonia | ➤ Sign Up | PRODUCT NAME: EVIPLERA - EMTRITSITABIIN/RILPIVIRIIN (HUEDRO-;REG NO/DATE: C(2011)8956 FINAL 28.11.2011 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
